Inactive Instrument

Taiwan Liposome Company, Ltd. Stock

4152

TW0004152004

Biotechnology & Medical Research

Chart Taiwan Liposome Company, Ltd.

Duration

Period

Style

Dynamic Chart

Latest news about Taiwan Liposome Company, Ltd.

Endo Ventures Limited Executes Agreement with Taiwan Liposome Company, Ltd. to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain	22-06-13	CI
TLC BioSciences Announces Publication of Tlc599 Phase Ii Results in Arthritis Research & Therapy	22-03-07	CI
Woods Investment Company, Ltd. completed the acquisition of Taiwan Liposome Company, Ltd. from a group of sellers.	21-10-07	CI
Taiwan Liposome Company, Ltd.(NasdaqGM:TLC) dropped from NASDAQ Composite Index	21-09-29	CI
Taiwan Liposome : to Voluntary Delist From Nasdaq	21-09-08	MT
TAIWAN LIPOSOME : HC Wainwright Lowers Taiwan Liposome to Neutral From Buy, Price Target to $7.50 From $11	21-07-13	MT
TAIWAN LIPOSOME : Laidlaw Downgrades Taiwan Liposome to Hold From Buy	21-07-07	MT
Woods Investment Company, Ltd. agreed to acquire Taiwan Liposome Company, Ltd. from a group of sellers for TWD 9.2 billion.	21-07-04	CI
Taiwan Liposome Company, Ltd. and Endo International plc Enter a Commercialization Agreement for A Liposomal Product	21-07-01	CI
TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India	21-05-27	CI
Taiwan Liposome : Working With Zydus Healthcare to Provide Supply of AmphoTLC in India	21-05-26	MT
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India	21-05-26	CI
Taiwan Liposome : TLC Secures India's Approval For Mucormycosis Treatment AmphoTLC	21-05-25	MT
Taiwan Liposome : Earnings Flash (TLC) TLC Posts Q1 Loss $-0.08	21-05-14	MT
Taiwan Liposome Company, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI

More news

Analyst Recommendations on Taiwan Liposome Company, Ltd.

TAIWAN LIPOSOME : HC Wainwright Lowers Taiwan Liposome to Neutral From Buy, Price Target to $7.50 From $11	21-07-13	MT
TAIWAN LIPOSOME : Laidlaw Downgrades Taiwan Liposome to Hold From Buy	21-07-07	MT

More recommendations

Press releases Taiwan Liposome Company, Ltd.

Taiwan Liposome : Filings with the Taipei Exchange’s Market Observation Post System, dated October 8, 2021 - Form 6-K	21-10-08	PU
Taiwan Liposome : TLC to Present at Upcoming Virtual Investor Conferences	21-09-09	PU
Taiwan Liposome : TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares (Form 6-K)	21-09-08	PU
Taiwan Liposome : ANNUAL GENERAL MEETING MINUTES (Form 6-K)	21-08-27	PU
Taiwan Liposome : 2021 First EGM Minutes	21-08-26	PU

More press releases

Managers and Directors - Taiwan Liposome Company, Ltd.

Managers	Title	Age	Since
Chih Hung Yeh CEO	Chief Executive Officer	52	02-02-28
Kee Lung Hong CHM	Chairman	81	97-11-09

Members of the board	Title	Age	Since
Mao Jung Lin BRD	Director/Board Member	69	17-05-30
Kee Lung Hong CHM	Chairman	81	97-11-09
Chih Hung Yeh CEO	Chief Executive Officer	52	02-02-28

More insiders

Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.35%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.84%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B